Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$291.0m

Aclaris Therapeutics Management

Management criteria checks 3/4

Aclaris Therapeutics' CEO is Neal Walker, appointed in Jul 2012, has a tenure of 12.42 years. directly owns 1.34% of the company’s shares, worth $3.90M. The average tenure of the management team and the board of directors is 1.9 years and 10.3 years respectively.

Key information

Neal Walker

Chief executive officer

US$73.5k

Total compensation

CEO salary percentagen/a
CEO tenure12.4yrs
CEO ownership1.3%
Management average tenure1.9yrs
Board average tenure10.3yrs

Recent management updates

Recent updates

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Neal Walker's remuneration changed compared to Aclaris Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$4mUS$550k

-US$82m

Sep 30 2018n/an/a

-US$81m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$86m

Dec 31 2017US$810kUS$510k

-US$50m

Compensation vs Market: Neal's total compensation ($USD73.50K) is below average for companies of similar size in the US market ($USD1.44M).

Compensation vs Earnings: Neal's compensation has been consistent with company performance over the past year.

CEO

Neal Walker (54 yo)

12.4yrs

Tenure

US$73,500

Compensation

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...

Leadership Team

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder12.4yrsUS$73.50k1.34%
$ 3.9m
Kevin Balthaser
Chief Financial Officer1.9yrsUS$2.34m0.023%
$ 67.2k
Joseph Monahan
Chief Scientific Officer3.9yrsUS$2.26m0.16%
$ 467.8k
James Loerop
Chief Business Officer2.9yrsUS$2.33m0.032%
$ 92.5k
Hugh M. Davis
Presidentless than a yearno datano data
Matthew Rothman
General Counsel & Corporate Secretary2.5yrsno datano data
Jon Jacobsen
Senior Vice President of Chemistryno datano datano data
Steve Tucker
Senior Vice President of Project Leadershipless than a yearno datano data
Ajay Aggarwal
Senior Vice President of Clinical Developmentless than a yearno datano data
Steven Knapp
Executive Vice Presidentless than a yearno datano data

1.9yrs

Average Tenure

59yo

Average Age

Experienced Management: ACRS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder12.4yrsUS$73.50k1.34%
$ 3.9m
Hugh M. Davis
Presidentless than a yearno datano data
Vincent Milano
Independent Director4.9yrsUS$180.38k0.012%
$ 34.1k
Mark Bradshaw
Member of Advisory Boardno datano datano data
James Leyden
Member of Advisory Boardno datano datano data
Klaus Theobald
Member of Advisory Boardno datano datano data
Anand Mehra
Independent Director10.3yrsUS$194.38k0.66%
$ 1.9m
Guy Webster
Member of Advisory Boardno datano datano data
Christopher Molineaux
Lead Independent Director10.9yrsUS$206.88k0.050%
$ 144.6k
Kenneth Beer
Member of Advisory Boardno datano datano data
Leslie Baumann
Member of Advisory Boardno datano datano data
Andrew Ondo
Member of Advisory Boardno datano datano data

10.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ACRS's board of directors are seasoned and experienced ( 10.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI